Embozene™ and Tandem™ are now sold by Varian.
Tumour Management > Clinical
Achieving deep targeted embolisation using small microspheres
First study on Safety & Efficacy using 40 µm Embozene™ TANDEM microspheres
« We have chosen Tandem 40μm for their small sizes and calibration as well as for size stability, post loading change being inferior to 5%. Among our expectations, a theoritical deeper penetration. So less risk of angiogenesis due to hypoxic effect »
Dr Giorgio Greco, Istituto Nazionale del Tumori, Milano.
Impact of microparticle size on embolisation effect
Case report: use of 40 μm microspheres with doxorubicin in patient with hepatitis C cirrhosis and Child-Pugh classification C as bridging therapy
“Histological examinations showed the presence of doxorubicin beads within the interstitium of the tumour, the deepest level achievable.”
Hoi Lam She, Princess Margaret Hospital, Hong Kong